Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense versus standard epirubicin + cyclophosphamide for advanced breast cancer
ACTRN12605000478617Phase 3Completed
- Sponsor
- Breast Cancer Trials
- Start
- Feb 1994
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cyclophosphamide and filgrastim in breast cancer (2 arms), sponsored by Breast Cancer Trials. Primary endpoints: Quality of life / quality-adjusted time without symptoms or toxicity, Survival duration and 4 more. Started Feb 1994; status: completed.
02
Drugs
epirubicincyclophosphamidefilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12605000478617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000478617.